Orgenesis Inc. (NasdaqCM:ORGS) agreed to acquire 25% stake in Octomera LLC from MM OS Holdings, L.P. on January 31, 2024. In exchange, MM OS Holdings shall receive a royalty of 5% of the net revenue of Octomera?s cell processing services, for the three calendar years 2025-2027
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.543 USD | +2.26% | -6.38% | +8.45% |
Apr. 16 | North American Morning Briefing : Powell Comments, -2- | DJ |
Apr. 15 | Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
+8.45% | 18.08M | |
-5.21% | 182B | |
+4.10% | 114B | |
-3.13% | 68.38B | |
+6.19% | 52.46B | |
+8.11% | 44.25B | |
+7.52% | 43.55B | |
+24.89% | 32.69B | |
+17.85% | 26.73B | |
-0.58% | 25.79B |
- Stock Market
- Equities
- ORGS Stock
- News Orgenesis Inc.
- Orgenesis Inc. agreed to acquire 25% stake in Octomera LLC from MM OS Holdings, L.P.